Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Cancer

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Adherence to international pharmacogenomic recommendations in pediatric cancer care: a cohort analysis embedded within the MARVEL-PIC randomized trial.

Pharmacogenomics·2026

Same author

Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.

Future oncology (London, England)·2026

Same author

BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.

International journal of clinical oncology·2026

Same author

Tacrolimus in Pediatric Solid Organ Transplant Recipients: A Retrospective Cohort Study.

Pediatric transplantation·2026

Same author

Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Impact of Spiritual Wellbeing in Advanced Cancer Patients Receiving Genomic Test Results.

Psycho-oncology·2026

Search research articles

Related Experiment Video

Updated: Jun 5, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

Liposarcoma: molecular genetics and therapeutics.

Rachel Conyers¹, Sophie Young, David M Thomas

¹Sarcoma Genomics & Genetics, Peter MacCallum Cancer Centre, 12 St Andrews Place, East Melbourne, VIC 3002, Australia.

|January 22, 2011

Summary

This review explores the molecular pathogenesis of three liposarcoma subtypes, detailing their genetic basis and potential therapeutic targets. Understanding these sarcoma molecular profiles is key for future treatment strategies.

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Related Experiment Videos

Last Updated: Jun 5, 2026

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Area of Science:

Oncology
Molecular Biology
Genetics

Background:

Sarcomas are diverse tumors characterized by varied genetic underpinnings.
Cytogenetic abnormalities in sarcomas include translocations, amplifications, and chromosomal losses.
Liposarcomas, a subtype of sarcoma, exhibit a range of molecular alterations across their different classifications.

Purpose of the Study:

To review the molecular pathogenesis of three main liposarcoma subtypes: well-differentiated/dedifferentiated, myxoid/round cell, and pleomorphic liposarcoma.
To discuss the genetic basis and molecular mechanisms driving these liposarcoma subtypes.
To explore potential future therapeutic interventions based on molecular understanding.

Main Methods:

Literature review of molecular pathogenesis in liposarcoma.
Analysis of genetic rearrangements and chromosomal abnormalities specific to liposarcoma subtypes.
Synthesis of current knowledge on molecular drivers and therapeutic targets.

Main Results:

Detailed outline of the molecular pathogenesis for well-differentiated/dedifferentiated liposarcoma.
Explanation of the molecular basis for myxoid/round cell liposarcoma.
Overview of the genetic landscape and molecular characteristics of pleomorphic liposarcoma.

Conclusions:

Liposarcoma subtypes possess distinct molecular profiles that dictate their pathogenesis.
Understanding the specific molecular alterations is crucial for developing targeted therapies.
Future research should focus on leveraging these molecular insights for novel therapeutic strategies in sarcoma treatment.